While reporting its first-quarter financial results yesterday, French drug giant Sanofi said that sales in its diabetes unit fell 3% year-over-year to 1.8 billion euros ($2 billion) and would likely lag for the rest of the year, due to competition in the U.S. The vaccines unit also saw its sales decline—by nearly 5% in the first quarter to 697 million euros ($784 million)—but Sanofi and many of the analysts who follow it are confident vaccines will help pull it out of its slump. Sanofi makes some of the world’s most widely used vaccines to protect against such diseases as influenza, polio, and meningitis. And now it’s preparing to launch a vaccine to fight dengue, a mosquito-borne illness that affects more than 50 million people a year in 100 countries.
Hey, check out all the research scientist jobs. Post your resume today!
